Trial characteristics
| Trial . | N . | Phase . | Period of accrual . | Treatment induction* . | Population . |
|---|---|---|---|---|---|
| CALGB 10201 | 506 | 3 | 2003-2006 | 7 + 3 ± oblimersen | Older AML |
| CALGB 10503 | 546 | 2 | 2007-2011 | 7 + 3 + 3 | Younger AML |
| CALGB 10603 | 717 | 3 | 2008-2015 | 7 + 3 ± midostaurin | Younger FLT3-mutated AML |
| CALGB 10801 | 61 | 2 | 2011-2014 | 7 + 3 + dasatinib | CBF AML |
| CALGB 11001 | 54 | 2 | 2011-2014 | 7 + 3 + sorafenib | Older FLT3-mutated AML |
| Trial . | N . | Phase . | Period of accrual . | Treatment induction* . | Population . |
|---|---|---|---|---|---|
| CALGB 10201 | 506 | 3 | 2003-2006 | 7 + 3 ± oblimersen | Older AML |
| CALGB 10503 | 546 | 2 | 2007-2011 | 7 + 3 + 3 | Younger AML |
| CALGB 10603 | 717 | 3 | 2008-2015 | 7 + 3 ± midostaurin | Younger FLT3-mutated AML |
| CALGB 10801 | 61 | 2 | 2011-2014 | 7 + 3 + dasatinib | CBF AML |
| CALGB 11001 | 54 | 2 | 2011-2014 | 7 + 3 + sorafenib | Older FLT3-mutated AML |
CBF, core binding factor.
7 + 3, anthracycline or cytarabine on days 1-7 and daunorubicin on days 1-3; 7 + 3 + 3, anthracycline or cytarabine on days 1-7, daunorubicin on days 1-3, and etoposide on days 1-3.